Mineralys Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 4 trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-12-22DayLorundrostatMineralys Therapeutics Inc. · MLYSCompany-disclosed PDUFA goal dateAnnounced review targethypertension in combination with other antihypertensive drugsOpen original source
Read source excerpt

We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2026-12-22DayLorundrostatMineralys Therapeutics Inc. · MLYSCompany-disclosed PDUFA goal dateAnnounced review targettreatment of hypertension in combination with other antihypertensive drugsOpen original source
Read source excerpt

The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Placebo-adjusted change from baseline in automated office blood pressure (AOBP) systolic blood pressure (SBP) at Week 4 Measure: Incidence and severity of adverse events (AEs). After: Measure: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4.

Check registry source

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 1400 participants (planned). After: 1076 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 30 Dec 2025.

Check registry source